A comparison of the effects of a chlamydial vaccine administered during or after a C. muridarum urogenital infection of female mice

Vaccine

Volumn 29, Issue 38, 2011, Pages 6505-6513

  Carey, Alison ^a,b   Cunningham, Kelly ^a   Andrew, Dean ^a   Hafner, Louise ^a   Timms, Peter ^a   Beagley, Kenneth ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Chlamydia; Pathology; Timing of vaccination

Indexed keywords

ANTIBODY; CHLAMYDIA VACCINE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; OUTER MEMBRANE PROTEIN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SMALL CHAIN PROTEIN SUBUNIT B; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIUM DETECTION; CHLAMYDIASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; FEMALE; HISTOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UROGENITAL TRACT INFECTION; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; RODENT DISEASES; URINARY TRACT INFECTIONS; VACCINATION;

EID: 80051667802     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.012     Document Type: Article

References (41)

1. WHO Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates 2001, World Health Organisation, Geneva.
2. Beagley K., Timms P. Chlamydial trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol 2000, 48:47-68.
3. CDC.Centres for Disease Control and Prevention Sexually transmitted disease surveillance 2007, Department of Health and Human Services, Atlanta, GA, December 2008.
4. Hafner L.M., McNeilly C. Vaccines for Chlamydia infections of the female genital tract. Future Microbiol 2008, 3(1):67-77.
5. Paavonen J., Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 1999, 5(September (5)):433-447.
6. Li W., Murthy A.K., Guentzel M.N., Seshu J., Forsthuber T.G., Zhong G., et al. Antigen-specific CD4+ T cells produce sufficient IFN-{gamma} to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol 2008, 180(March (5)):3375-3382.
7. Rank R.G., Barron A.L. Humoral immune response in acquired immunity to chlamydial genital infection of female guinea pigs. Infect Immun 1983, 39(January (1)):463-465.
8. Darville T., Andrews C.W., Sikes J.D., Fraley P.L., Rank R.G. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. Infect Immun 2001, 69(June (6)):3556-3561.
9. Williams D.M., Magee D.M., Bonewald L.F., Smith J.G., Bleicker C.A., Byrne G.I., et al. A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun 1990, 58(June (6)):1572-1576.
10. Ault K.A., Tawfik O.W., Smith-King M.M., Gunter J., Terranova P.F. Tumor necrosis factor-alpha response to infection with Chlamydia trachomatis in human fallopian tube organ culture. Am J Obstet Gynecol 1996, 175(5):1242-1245.
11. Stephens R.S. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 2003, 11(1):44-51.
12. Hvid M., Baczynska A., Deleuran B., Fedder J., Knudsen H.J., Christiansen G., et al. Interleukin-1 is the initiator of fallopian tube destruction during Chlamydia trachomatis infection. Cell Microbiol 2007, 9(July (12)):2795-2803.
13. Scott J.G., Kerrich J.E. Live trachoma vaccine and topical therapy. Br J Ophthalmol 1971, 55(March (3)):189-191.
14. Grayston J.T., Wang S.-P., Yang Y.-F., Woolridge R.L. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J Exp Med 1962, 115(May (5)):1009-1022.
15. Wang S., Grayston J.T. Pannus with experimental trachoma and inclusion conjunctivitis agent infection of Taiwan monkeys. Am J Ophthalmol 1967, 63(May (5)):1133-1145.
16. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am J Ophthalmol 1967, 63(May (5)):1615-1630.
17. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis Vaccine. Nat Rev Immunol 2005, 5(2):149-161.
18. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 2004, 72(February (2)):1019-1028.
19. Skelding K.A., Hickey D.K., Horvat J.C., Bao S., Roberts K.G., Finnie J.M., et al. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine 2006, 24(3):355-366.
20. Barker C.J., Beagley K.W., Hafner L.M., Timms P. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 2008, 26(10):1285-1296.
21. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(3):1161-1176.
22. Carey A.J., Cunningham K.A., Hafner L.M., Timms P., Beagley K.W. Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunol Cell Biol 2009, 87(4):337-343.
23. Brunham R.C., Rekart M.L. The arrested immunity hypothesis and the epidemiology of Chlamydia control. Sex Transm Dis 2008, 35(1):53-54.
24. Terada K., Niizuma T., Ogita S., Kataoka N. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002, 20(31-32):3638-3643.
25. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. Med Engl J N 2002, 347(21):1652-1661.
26. Matyszak M.K., Young J.L., Gaston J.S. Uptake and processing of Chlamydia trachomatis by human dendritic cells. Eur J Immunol 2002, 32(3):742-751.
27. Rey-Ladino J., Koochesfahani K.M., Zaharik M.L., Shen C., Brunham R.C. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect Immun 2005, 73(3):1568-1577.
28. Kaiko G.E., Phipps S., Hickey D.K., Lam C.E., Hansbro P.M., Foster P.S., et al. Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity. J Immunol 2008, 180(4):2225-2232.
29. Young L.J., Wilson N.S., Schnorrer P., Mount A., Lundie R.J., La Gruta N.L., et al. Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. PNAS 2007, 104(45):17753-17758.
30. Zhong G., Fan T., Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999, 189(12):1931-1938.
31. Govan V., Rybicki E., Williamson A.L. Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J 2008, 5:45.
32. Trimble C.L., Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 2009, 10(10):975-980.
33. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
34. Puls R.L., Emery S. Therapeutic vaccination against HIV: current progress and future possibilities. Clin Sci (Lond) 2006, 110(1):59-71.
35. Shah A., Schripsema J., Imtiaz M., Sigar I., Kasimos J., Matos P., et al. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex Transm Dis 2005, 32(1):49-56.
36. de la Maza L.M., Pal S., Khamesipour A., Peterson E.M. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun 1994, 62(5):2094-2097.
37. Ramsey K.H., Miranpuri G.S., Sigar I.M., Ouellette S., Byrne G.I. Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun 2001, 69(8):5131-5137.
38. Mansour R.T., Aboulghar M.A., Serour G.I., Riad R. Fluid accumulation of the uterine cavity before embryo transfer: a possible hindrance for implantation. J In Vitro Fert Embryo Transf 1991, 8(3):157-159.
39. Mukherjee T., Copperman A.B., McCaffrey C., Cook C.A., Bustillo M., Obasaju M.F. Hydrosalpinx fluid has embryotoxic effects on murine embryogenesis: a case for prophylactic salpingectomy. Fertil Steril 1996, 66(5):851-853.
40. Bignold L.P. Cytokines and inflammation: modified "Miles-Wilhelm" criteria for assessing the likely roles of these substances in vivo. Pathology 1989, 21(3):200-206.
41. Toth M., Jeremias J., Ledger W.J., Witkin S.S. In vivo tumor necrosis factor production in women with salpingitis. Surg Gynecol Obstet 1992, 174(5):359-362.